<DOC>
	<DOCNO>NCT00352859</DOCNO>
	<brief_summary>The purpose study see take interferon gemcitabine along sorafenib stop advance renal cell cancer become bad people . To , sorafenib along gemcitabine interferon compare treatment gemcitabine interferon alone . More safety information sorafenib also collect . About 260 patient progressed renal cell cancer study .</brief_summary>
	<brief_title>Phase IV Randomization On-Going Treatment Evaluate Sustained Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female patient 18 year age advance RCC receive sorafenib first systemic antitumor therapy RCC prior randomization Patients must previously tolerate minimum dose sorafenib 400 mg daily least six week prior study entry radiographically document progressive disease sorafenib Patients must experience clinical benefit , partial response , complete response stable disease previous course sorafenib therapy Life expectancy &gt; 12 week Patients must meet Memorial SloanKettering Cancer Center ( MSKCC ) risk category low medium randomization Patients must give write informed consent prior study specific screen procedure understand patient right withdraw study time , without prejudice Patients must least one unidimensional measurable lesion CTscan MRI accord Response Evaluation Criteria Solid Tumors ( RECIST ) Patients must brain metastasis Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 In addition , follow patient may include , provide inclusion exclusion criterion meet Patients receive vaccine cG250 ( monoclonal antibody carbonic anhydrase IX ) HSPPC96 ( Heat Shock Protein Peptide Complex 96 ) eligible provide received systemic anticancer therapy Patients enrol ARCCS treatment protocol Patients must experience three week document disease progression randomization Any medical condition require use systemic corticosteroid IFN therapy Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) cancer curatively treat within last three year prior study entry Severe renal impairment receive dialysis More two week interruption sorafenib dose immediately prior randomization Patients best response disease progression previous course sorafenib Patients meet MSKCC high risk category randomization Hemorrhagic episode &gt; = Grade 2 NCI CTC AE v3.0 within last six month History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active cardiovascular disease ( MI six month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension Active clinically serious bacterial fungal infection ( &gt; = Grade 2 NCI CTCAE v3.0 ) Known history Human Immunodeficiency Virus ( HIV ) infection chronic hepatitis B C Symptomatic metastatic brain meningeal tumor unless patient &gt; six month definitive therapy , negative CNS imaging study within four week study entry , clinically stable steroid . The patient must undergo acute steroid taper Patients seizure disorder require medication ( steroids antiepileptic ) Ongoing substance abuse , medical , psychological social condition may interfere patient participation study evaluation study result Known suspect allergy investigational agent agent give association trial , include history sensitivity E. coliderived product Any condition unstable could jeopardise safety patient his/her compliance study . Patients history severe depression ; patient clinically significant active autoimmune disorder ; history organ allograft Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within seven day start study treatment . Both men woman enrol trial must use adequate birth control measure course trial Patients significant surgical procedure within past four week exclude Excluded Therapies Medications , Previous Concomitant : Any prior concurrent systemic anticancer therapy include chemotherapy , monoclonal antibody , hormonal therapy investigational therapy , except bisphosphonates sorafenib Biological response modifier , GCSF GMCSF , within three week prior study entry study . GCSF hematopoietic growth factor may use management acute toxicity febrile neutropenia medically indicate discretion Investigator . However , may substitute require dose reduction study drug Patients take erythropoietin permit provide dose adjustment undertaken within two month prior study study Concomitant rifampicin St. John 's Wart Palliative therapy allow , patient may receive palliative supportive care underlie illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>RCC</keyword>
</DOC>